Our Solution
The Angiomedix Solution: AngioView
- Cardiovascular-specific acetylcholine chloride formulation
- Stable, on-label drug for coronary function testing, overcoming access barriers of off-label ophthalmic solutions.
- Pre-filled syringe with purpose-built safety injector to prevent arrhythmias and simplify workflow for clinicians.
- First-in-class diagnostic test for coronary vasomotor dysfunction
- Enables precise, guideline-recommended diagnosis of microvascular disease and coronary vasospasm (INOCA), conditions often missed by standard tests and disproportionately affecting women.
- Seamless integration into cardiac catheterization labs
- Designed to complement existing technologies and fit standardized protocols developed by leading experts.
- Lowers the barrier to adoption for new users and sites.
- Proven clinical impact
- 2.6x higher diagnostic yield compared to standard care; modifies treatment in 60% of patients.
- Associated with improved symptoms, quality of life, and medication optimization—especially for women.
- Safety validated in >12,000 patients with <0.5% complication rate.
- Scalable and ready for market expansion
- Only 10% of U.S. cath labs currently offer this testing—Angiomedix enables rapid scale-up.
- Supported by ongoing large-scale clinical studies and partnerships with leading cardiovascular centers.
